Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
US-10501427-B2 · Dec 10, 2019 · US
Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
US11059798B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11059798-B2 |
| Application number | US-201916672870-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 4, 2019 |
| Priority date | Jun 20, 2011 |
| Publication date | Jul 13, 2021 |
| Grant date | Jul 13, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D 1 and D 2 as well as the 5HT 2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating schizophrenia, schizophreniform disorder, or schizoaffective disorder in a subject in need thereof comprising administration of an effective amount of a hydrogen fumarate salt of a deuterium enriched compound of formula Y: wherein, R 1 -R 10 are independently hydrogen or deuterium, wherein at least two of R 1 -R 10 are deuterium. 2. The method of claim 1 , further comprising administration of at least one neuroleptic agent. 3. The method of claim 2 , wherein the neuroleptic agent is selected from the group consisting of sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone, and osanetant. 4. The method of claim 1 , wherein the compound is 5. The method of claim 1 , wherein the compound is 6. The method of claim 1 , wherein the compound is 7. The method of claim 1 , wherein the compound is 8. The method of claim 1 , wherein the compound is 9. The method of claim 1 , wherein the compound is
Assignees
Inventors
Classifications
Drugs for disorders of the nervous system · CPC title
containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine · CPC title
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title
- C07D295/073Primary
with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings · CPC title
having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11059798B2 cover?
- The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D 1 and D 2 as well as the 5HT 2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising …
- Who is the assignee on this patent?
- H Lundbeck As
- What technology area does this patent fall under?
- Primary CPC classification C07D295/073. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).